4,111 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Axis Wealth Partners LLC

Axis Wealth Partners LLC bought a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,111 shares of the company's stock, valued at approximately $269,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new position in AstraZeneca during the 3rd quarter valued at about $28,000. Albion Financial Group UT grew its stake in shares of AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock valued at $40,000 after buying an additional 248 shares in the last quarter. Groupama Asset Managment grew its stake in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company's stock valued at $42,000 after buying an additional 101,225 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of AstraZeneca in the 3rd quarter valued at approximately $45,000. Finally, Versant Capital Management Inc grew its stake in shares of AstraZeneca by 2,618.5% in the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company's stock valued at $48,000 after buying an additional 707 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Trading Up 0.0 %

AstraZeneca stock traded up $0.03 during mid-day trading on Friday, hitting $77.50. The stock had a trading volume of 7,022,104 shares, compared to its average volume of 5,679,263. The stock has a 50-day simple moving average of $70.83 and a two-hundred day simple moving average of $72.65. The stock has a market capitalization of $240.34 billion, a PE ratio of 34.29, a P/E/G ratio of 1.42 and a beta of 0.41. AstraZeneca PLC has a 12 month low of $62.75 and a 12 month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

Remove Ads

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be paid a $1.03 dividend. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. This represents a yield of 2%. AstraZeneca's dividend payout ratio is presently 91.15%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. Morgan Stanley assumed coverage on AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating for the company. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.